三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
依沃西对比帕博利珠单抗治疗PD-L1阳性(TPS≥1%)NSCLC临床数据(非头对头对比)
依沃西对比帕博利珠单抗治疗PD-L1阳性(TPS≥1%)NSCLC临床数据(非头对头对比)
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:62KB
图片尺寸:1830*373
同报告图片
/
4
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
所属报告:
康方生物-公司投资价值分析报告:百尺竿头聚焦全球首创疗法的双抗龙头-230209(70页).pdf
打包全文图表
相关数据
ADC联合IO单抗治疗一线NSCLC全球三期研究启动时间
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
收藏
行业数据
2026-07-14
原图定位
查看详情
KRASG12C一线治疗NSCLC竞争格局(截至2026-6-25)
收藏
竞争格局
2026-07-01
原图定位
查看详情
全球KRASG12C突变的NSCLC发病人数
收藏
行业数据
2026-07-01
原图定位
查看详情
中国KRASG12C突变的NSCLC发病人数
收藏
行业数据
2026-07-01
原图定位
查看详情
SHR-A2009用于EGFR突变型NSCLC的1期临床研究结果
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
收藏
行业数据
2026-05-28
原图定位
查看详情
SHR-A2009用于一线NSCLC患者的研究结果
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
收藏
行业数据
2026-05-28
原图定位
查看详情
依沃西为全球首个在三期临床中头对头击败K药的新药,PFS强阳性(HR=0.51)
收藏
行业数据
2026-03-31
原图定位
查看详情
HARMONi-6试验主要终点:依沃西+化疗较对照臂PFS提升4.2个月(HR=0.60)
收藏
行业数据
2026-03-31
原图定位
查看详情
PD(L)1*VEGF双抗单药针对一线NSCLC数据汇总
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
收藏
行业数据
2026-03-13
原图定位
查看详情
各药物针对IO耐药NSCLC临床数据汇总
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
收藏
行业数据
2026-03-13
原图定位
查看详情
驱动基因阴性晚期NSCLC治疗格局
收藏
竞争格局
2026-02-24
原图定位
查看详情
NSCLC1L全球竞争格局AK112BNT327707
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
收藏
竞争格局
2026-01-28
原图定位
查看详情
SI-B001针对PD-(L1)抑制剂治疗失败的野生型NSCLC的mPFS数据
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
收藏
行业数据
2025-12-26
原图定位
查看详情
TPS因子10分组及多空对冲净值走势(2006/01-2025/11)
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
收藏
行业数据
2025-12-05
原图定位
查看详情
TPS因子的10分组多空对冲绩效指标(2006/01-2025/11)
fCDmjIfmoIcgICAgICAgICB8IOWFqOS9k0HogqEgICB8CnwtLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS18Cnwg5bm05YyW5pS255uK546HICAgfCAzOS4zMCUgICAgIHwKfCDlubTljJbms6LliqjnjocgICB8IDE1LjcxJSAgICAgfAp8IOS/oeaBr+avlOeOhyAgICAgfCAyLjUwICAgICAgIHwKfCDmnIjluqbog5znjocgICAgIHwgNzcuNjQlICAgICB8Cnwg5pyA5aSn5Zue5pKk546HICAgfCAxOC4xOSUgICAgIHwKCuaVsOaNruadpea6kO+8mldpbmQg6LWE6K6v77yM5Lic5ZC06K+B5Yi456CU56m25omA
收藏
行业数据
2025-12-05
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
依沃西单药治疗 PD-L1 阳性 NSCLC 的 III 期临床试验目前处于患者入组阶段,该适应症已获得 CDE 突破性疗法认证。我们预计患者入组工作有望在 2023H2 完成,试验数据有望在 2024 年读出。
行业数据
原图定位
当前图表所属:
康方生物-公司投资价值分析报告:百尺竿头聚焦全球首创疗法的双抗龙头-230209(70页).pdf
卡度尼利及其他免疫疗法用于二线/三线宫颈癌治疗临床数据(非头对头对比)
PD-(L)1/CTLA-4双抗全球研发进展
纳武利尤单抗联用或不联用伊匹木单抗临床数据
国内CTLA-4单抗中后期临床试验进展(II期及以上)
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》